Compare Charles River Laboratories Intl. Inc (CRL) vs Schlumberger NV (SLB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Charles River Laboratories Intl. Inc vs Schlumberger NV — how do they compare? Charles River Laboratories Intl. Inc trades at $301.79 (market cap $14.23B), while Schlumberger NV trades at $48.95 (market cap $72.69B). The key difference: Schlumberger NV is far larger — about 5.1× Charles River Laboratories Intl. Inc's market cap, and Schlumberger NV pays a 2.41% dividend while Charles River Laboratories Intl. Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Charles River Laboratories Intl. Inc for 33 Days and Schlumberger NV for 99 Days on average.
| CRL | SLB | |
|---|---|---|
Market Cap | $14.23B | $72.69B |
Volume | 1,176,885 | 16,228,451 |
Sector | Health | Energy |
52-Week High | $310.77 | $60.10 |
52-Week Low | $149.93 | $31.72 |
Typical Hold Time | 33 Days | 99 Days |
Enterprise Value | $17.06B | $81.42B |
Dividend Yield | — | 2.41% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Charles River Laboratories (CRL) trades at $298.00, down 0.77% on the day, with a bullish technical signal supported by moving averages. The company has beaten earnings estimates for three consecutive quarters, though it reported a net loss of -$144.34M for 2025. Analyst consensus is strongly positive with a $305.50 price target, and recent news highlights a strategic growth plan targeting 5%-7% revenue growth by 2030.
The stock's outlook is supported by strong analyst buy ratings and a clear growth strategy, but faces risks from negative profitability metrics and high valuation multiples. Investment opportunity hinges on successful execution of margin expansion and cost savings initiatives, while key risks include persistent net losses and competitive pressures in the healthcare services sector.
SLB trades at $48.98, up 2.13% today, with a bearish technical signal despite recent earnings beats. The company secured major contracts in Oman and Mozambique, expanding its international footprint. Revenue declined slightly to $35.71B in 2025, with net income margin at 8.53%. Analyst consensus remains strongly bullish with 85% buy ratings and a $64.58 price target, representing 32% upside potential.
SLB faces near-term headwinds from declining profit margins and bearish technical indicators, but strong contract wins and analyst optimism suggest long-term growth potential. Key risks include oil price volatility and execution challenges in new markets. The stock offers value at current levels for investors with a medium-to-long-term horizon.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Charles River Laboratories Intl. Inc
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →About Schlumberger NV
Schlumberger is the largest oilfield service firm in the world, with expertise in myriad disciplines, including reservoir performance, well construction, production enhancement, and more recently, digital solutions. It maintains a reputation as one of the industry's leading innovators, which has earned it dominant share in numerous end markets.
Read more on SLB →
